RT Journal Article
SR Electronic
T1 Integrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.20.21250155
DO 10.1101/2021.01.20.21250155
A1 Courraud, Jeremie
A1 Chater-Diehl, Eric
A1 Durand, Benjamin
A1 Vincent, Marie
A1 del Mar Muniz Moreno, Maria
A1 Boujelbene, Imène
A1 Drouot, Nathalie
A1 Genschik, Loréline
A1 Schaefer, Elise
A1 Nizon, Mathilde
A1 Gerard, Bénédicte
A1 Abramowicz, Marc
A1 Cogné, Benjamin
A1 Bronicki, Lucas
A1 Burglen, Lydie
A1 Barth, Magalie
A1 Charles, Perrine
A1 Colin, Estelle
A1 Coubes, Christine
A1 David, Albert
A1 Delobel, Bruno
A1 Demurger, Florence
A1 Passemard, Sandrine
A1 Denommé, Anne-Sophie
A1 Faivre, Laurence
A1 Feger, Claire
A1 Fradin, Mélanie
A1 Francannet, Christine
A1 Genevieve, David
A1 Goldenberg, Alice
A1 Guerrot, Anne-Marie
A1 Isidor, Bertrand
A1 Johannesen, Katrine M.
A1 Keren, Boris
A1 Kibæk, Maria
A1 Kuentz, Paul
A1 Mathieu-Dramard, Michele
A1 Demeer, Bénédicte
A1 Metreau, Julia
A1 Møller, Rikke Steensbjerre
A1 Moutton, Sébastien
A1 Pasquier, Laurent
A1 Pilekær Sørensen, Kristina
A1 Perrin, Laurence
A1 Renaud, Mathilde
A1 Saugier, Pascale
A1 Svane, Joane
A1 Thevenon, Julien
A1 Them, Frederic Tran Mau
A1 Tronhjem, Cathrine Elisabeth
A1 Vitobello, Antonio
A1 Layet, Valerie
A1 Birling, Marie-Christine
A1 Drunat, Severine
A1 Bayat, Allan
A1 Dubourg, Christèle
A1 Chehadeh, Salima El
A1 Fagerberg, Christina
A1 Mignot, Cyril
A1 Guipponi, Michel
A1 Bienvenu, Thierry
A1 Herault, Yann
A1 Thompson, Julie
A1 Willems, Marjolaine
A1 Mandel, Jean-Louis
A1 Weksberg, Rosanna
A1 Piton, Amélie
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.20.21250155.abstract
AB DYRK1A-related intellectual disability (ID) is among the most frequent monogenic form of ID. We refined the description of this disorder by reporting clinical and molecular data of forty individuals with ID harboring DYRK1A variants. We developed a combination of tools to interpret missense variants, which remains a major challenge in human genetics: i) a specific DYRK1A clinical score, ii) amino acid conservation data generated from one hundred of DYRK1A sequences across different taxa, iii) in vitro overexpression assays to study level, cellular localization, and kinase activity of DYRK1A mutant proteins, and iv) a specific blood DNA methylation signature. This integrative approach was successful to reclassify several variants as pathogenic. However, we questioned the involvement of some others, such as p.Thr588Asn, yet reported as pathogenic, and showed it does not cause obvious phenotype in mice, emphasizing the need to take care when interpreting variants, even those occurring de novo.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors also thank the Agence de Biomedecine and Fondation APLM for their financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Affected individuals were referred by clinical genetic services and a genetic testing was done as part of routine clinical care. All patients enrolled and/or their legal representative have signed informed consent for research use and authorization for publication. All the institutions received local IRB approval to use these data in research purpose. The main IRB approval was obtained from the Ethics Committee of the Strasbourg University Hospital (CCPPRB).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe variants have been sumbitted to clinvar. All data are available upon request